Taken together, drugs engineered to promote GIP, GLP-1 and GLP-2 receptor signalling may have potential to offer therapeutic promise for improving bone health in obesity and diabetes. Here, GLP2R is linked to obesity due to melanocortin 4 receptor deficiency.